From static to stirred: preparing your stem cell cultivation for commercialization
Cultivating quality cells for any application at large scale can be challenging; however, this is a key requirement of moving an investigational cell therapy product from the bench to the bedside. Regulatory bodies require assurance that a defined process will reliably and quantifiably generate large numbers of cells, so optimizing your workflow early in the development process is helpful.
At what point in your development should you consider cultivation method? How could choice of cultivation method affect ease of scale-up and regulatory pathway? How has technology developed in response to research and clinical needs? In this coffee chat, join experts from Eppendorf and the Cell and Gene Therapy Catapult to discover the answers to these questions and more!
This webinar was recorded on 8 September 2022.
What will you learn?
- The challenges and opportunities of stem cells therapeutically
- The advantages of using a stirred tank bioreactor
- Top tips to optimize your process development from static to stirred tank cultivation
- Characteristics to consider when selecting a stirred tank bioreactor
Who may this interest?
- Academic researchers looking to scale-up or spin-out an investigational therapy
- Commercial advanced therapy manufacturers
- Other cell culture stakeholders
Speakers
Sebastian Selzer
Strategic Portfolio Manager Bioprocess
Eppendorf Bioprocess Center (Hamburg, Germany)
Sebastian holds a degree in Biotechnology from the University of Applied Sciences Wiener Neustadt (Austria), and a Master in Intellectual Property Law and Management from the University of Strasbourg (France).
He has 14 years of experience in the bioprocess industry as a research and development engineer and manager. Prior to his current position at Eppendorf (Hamburg, Germany), he worked for DASGIP AG (Jülich, Germany) and was co-founder and managing director of PS Biotech GmbH (Herzogenrath, Germany), a spin-off from RWTH Aachen University (North Rhine-Westphalia, Germany).
Since 2019, he became part of the business portfolio management within the Eppendorf Bioprocess group, where he focused on the single use bioreactor product line, before transitioning into his current role. As strategic portfolio manager, he is responsible for the further strategic development of the product portfolio as well as managing external and internal stakeholders, partners and collaborators.
Juline Guenat
Senior Scientist, Innovative manufacturing
Cell and Gene Therapy Catapult (London, UK)
Juline has an Engineering degree in Biotechnology from the National School of Biomolecules Bordeaux (ENSTBB; France). Since completion, Juline has focused her career building her upstream bioprocessing expertise with practical industry experience. Juline has worked on vaccine development at UCB-Pharma (Belgium), developing her technical understanding of scalable, automated and closed suspension cell culture technologies and approaches used in large-scale production of monoclonal antibodies and fragment antigen-binding fragments (Fabs). Since joining the Cell and Gene Therapy Catapult (UK), Juline has further developed her versatile industrial experience, applied to the cell and gene therapy field. Her work has been focused on applying novel bioprocessing solutions and developing closed end to end platforms to facilitate advanced therapy manufacture, bridging the gap between research and commercialization.
Sponsored by
In association with
